Cargando…

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar

OBJECTIVES: The aim of the study was to assess the safety and efficacy of switching an etanercept originator to an etanercept biosimilar in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis patients. MATERIAL AND METHODS: In 162 patients etanercept...

Descripción completa

Detalles Bibliográficos
Autores principales:	Felis-Giemza, Anna, Chmurzyńska, Kornelia, Nałęcz-Janik, Jolanta, Romanowska-Próchnicka, Katarzyna, Świerkocka, Katarzyna, Wudarski, Mariusz, Olesińska, Marzena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2019
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911255/ https://www.ncbi.nlm.nih.gov/pubmed/31853152 http://dx.doi.org/10.5114/reum.2019.89516

Ejemplares similares

Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2020)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

IL-35, TNF-α, BAFF, and VEGF serum levels in patients with different rheumatic diseases
por: Wojdasiewicz, Piotr, et al.
Publicado: (2019)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Discrepancies in assessment of patients with rheumatoid arthritis and secondary Sjögren's syndrome by DAS28-ESR and DAS28-CRP
por: Romanowska-Próchnicka, Katarzyna, et al.
Publicado: (2016)

Clinical remission in juvenile idiopathic arthritis after termination of etanercept
por: Postępski, Jacek, et al.
Publicado: (2012)

Treatment of rheumatic diseases and hepatitis B virus coinfection
por: Felis-Giemza, Anna, et al.
Publicado: (2014)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
por: Ebbers, Hans C., et al.
Publicado: (2019)

The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding
por: Romanowska-Próchnicka, Katarzyna, et al.
Publicado: (2021)

Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
por: Thiele, Franz, et al.
Publicado: (2021)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Physicochemical Characterization of Altebrel™, a Proposed Etanercept Biosimilar
por: Fazel, Ramin, et al.
Publicado: (2019)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study
por: Carballo, Nuria, et al.
Publicado: (2022)

Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
por: Jaworski, Janusz, et al.
Publicado: (2019)

Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases
por: Felis-Giemza, Anna, et al.
Publicado: (2023)

Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali(®)) Versus Etanercept (Enbrel(®)) - Findings from a Nurse Survey in Europe
por: Thakur, Kunal, et al.
Publicado: (2016)

Etanercept in the treatment of rheumatoid arthritis
por: Haraoui, Boulos, et al.
Publicado: (2007)

Etanercept for Treating Rheumatoid Arthritis
por: Moreland, Larry W
Publicado: (2000)

Recognizing systemic sclerosis: comparative analysis of various sets of classification criteria
por: Romanowska-Próchnicka, Katarzyna, et al.
Publicado: (2016)

Revising diagnosis of juvenile idiopathic arthritis in adults: a single-center retrospective study
por: Felis-Giemza, Anna, et al.
Publicado: (2023)

Interleukin 6 blockage-induced neutropenia in a patient with rheumatoid arthritis and resolved hepatitis B
por: Chmielińska, Magdalena, et al.
Publicado: (2016)

Differential diagnosis of idiopathic inflammatory myopathies in adults – the first step when approaching a patient with muscle weakness
por: Szczęsny, Piotr, et al.
Publicado: (2018)

Plasma Glycosaminoglycans in Children with Juvenile Idiopathic Arthritis Being Treated with Etanercept as Potential Biomarkers of Joint Dysfunction
por: Wojdas, Magdalena, et al.
Publicado: (2022)

Etanercept treatment in juvenile idiopathic arthritis: The Polish registry
por: Żuber, Zbigniew, et al.
Publicado: (2011)

Haptoglobin and Its Related Protein, Zonulin—What Is Their Role in Spondyloarthropathy?
por: Chmielińska, Magdalena, et al.
Publicado: (2021)

Real-World Experience with Etanercept Therapy and the Switching Pattern among Korean Patients with Psoriasis after Withdrawal of Etanercept
por: Choi, Chong Won, et al.
Publicado: (2019)

New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2016)

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
por: Cho, Ick Hyun, et al.
Publicado: (2016)

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study
por: Larid, Guillaume, et al.
Publicado: (2022)

Challenges in the management of juvenile idiopathic arthritis with etanercept
por: Pain, Clare E, et al.
Publicado: (2009)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

Safety of etanercept in elderly subjects with rheumatoid arthritis
por: Lurati, Alfredomaria, et al.
Publicado: (2010)

Optimal dose of etanercept in the treatment of rheumatoid arthritis
por: Curtis, Elizabeth Mary, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_djctkfk2k8koofa14292p2ujp0